Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Emilio F. Stuart"'
Autor:
Emilio F. Stuart, Nick Clarke, Paul Alan Glossop, Neil Feeder, Strang Ross Sinclair, J. W. Watson, Jane L. Burrows, Amy S. Kenyon, Matthew D. Selby, Michael A. Trevethick, Sheena Patel, Rhys M. Jones, Kim James, Karen N. Wright, Dannielle Frances Roberts, Lyn H. Jones
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 25:5121-5126
A 1,2,4-triazole motif was employed as a bioisostere for the ester commonly used in muscarinic antagonists, and subsequent integrative conjugation to a β2 agonist quinolinone furnished a new class of bifunctional MABAs for the treatment of COPD. Med
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1b09018de8f7e915b91637ee9153193
https://doi.org/10.1016/j.bmcl.2015.10.008
https://doi.org/10.1016/j.bmcl.2015.10.008
Autor:
Emilio F. Stuart, Stuart Rozze, Fiona Macintyre, D. K. Walker, Michael A. Trevethick, Sandra Marina Monaghan, Michael Yeadon, Maw Graham Nigel, Patricia Wright, Simon John Mantell, Matthew D. Selby, Helene Chavaroche, Peter T. Stephenson, Arnaud Lemaitre, David V. Batchelor, Karen N. Wright, Lynsey Whitlock
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 19:4471-4475
COPD is a major cause of mortality in the western world. A(2A) agonists are postulated to reduce the lung inflammation that causes COPD. The cardiovascular effects of A(2A) agonists dictate that a compound needs to be delivered by inhalation to be th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b87c4b9e0c41f333bb6eb6cd6ff48d8f
https://doi.org/10.1016/j.bmcl.2009.05.027
https://doi.org/10.1016/j.bmcl.2009.05.027
Autor:
Adrian Barnard, Michael Yeadon, Simon John Mantell, Karen N. Wright, Mike Trevethick, Emilio F. Stuart
Publikováno v:
British Journal of Pharmacology. 155:463-474
Adenosine A2A receptor agonists may be important regulators of inflammation. Such conclusions have come from studies demonstrating that, (i) adenosine A2A agonists exhibit anti-inflammatory properties in vitro and in vivo, (ii) selective A2A antagoni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b389fb3b3f24e9751710877ac153b5f7
https://doi.org/10.1038/bjp.2008.329
https://doi.org/10.1038/bjp.2008.329
Autor:
D. K. Walker, Emilio F. Stuart, Arnaud Lemaitre, David V. Batchelor, Peter G. Dodd, Maw Graham Nigel, Helene Chavaroche, Sandra Marina Monaghan, Ruth F. Keir, Matthew D. Selby, Simon John Mantell, Tim J. Hobson, Michael A. Trevethick, Peter T. Stephenson, Stuart Rozze, Rhys M. Jones, Karen N. Wright, Michael Yeadon
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 18:1284-1287
COPD is a major cause of mortality in the western world. A(2A) agonists are postulated to reduce the lung inflammation that causes COPD. The cardiovascular effects of A(2A) agonists dictate that a compound needs to be delivered by inhalation to be th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9d0869ceb904523cd82b828bbd710e4
https://doi.org/10.1016/j.bmcl.2008.01.033
https://doi.org/10.1016/j.bmcl.2008.01.033
Autor:
Paul A, Glossop, Christine A L, Watson, David A, Price, Mark E, Bunnage, Donald S, Middleton, Anthony, Wood, Kim, James, Dannielle, Roberts, Ross S, Strang, Michael, Yeadon, Christelle, Perros-Huguet, Nicholas P, Clarke, Michael A, Trevethick, Ian, Machin, Emilio F, Stuart, Steven M, Evans, Anthony C, Harrison, David A, Fairman, Balaji, Agoram, Jane L, Burrows, Neil, Feeder, Craig K, Fulton, Barry R, Dillon, David A, Entwistle, Fiona J, Spence
Publikováno v:
Journal of medicinal chemistry. 54(19)
A novel tertiary amine series of potent muscarinic M(3) receptor antagonists are described that exhibit potential as inhaled long-acting bronchodilators for the treatment of chronic obstructive pulmonary disease. Geminal dimethyl functionality presen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::22c240e08044f99a090aa8ee4d570ee8
https://pubmed.ncbi.nlm.nih.gov/21870878
https://pubmed.ncbi.nlm.nih.gov/21870878
Autor:
Emilio F. Stuart, Nick Clarke, Maria Stanley, Michele Coghlan, Matthew Strawbridge, Susan Summerhill, Mike Yeadon, Sheena Patel, Christelle Perros-Huguet, Mike Trevethick, Stuart Marshall
Publikováno v:
A45. BRONCHODILATORS FOR COPD: OLD FAITHFULS AND NOVEL COMPOUNDS.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05ea5d7da0632c8acdba8d01b18a94de
https://doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1607
https://doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1607
Autor:
Craig K. Fulton, David Price, Kim James, Mark E. Bunnage, Sandra D. Newman, Sheena Patel, Jane L. Burrows, Emilio F. Stuart, Rachel Osborne, Stuart Marshall, Nick Clarke, Matthew D. Selby, Neil Feeder, David A. Entwistle, Helen Baldock, Rhys M. Jones, Michele Coghlan, Laura Hilton, Michael A. Trevethick, Karen N. Wright, David Fairman, Lyn H. Jones, Amy S. Kenyon
Publikováno v:
Bioorganicmedicinal chemistry letters. 21(9)
This paper describes the successful design and development of dual pharmacology β-2 agonists-M3 antagonists, for the treatment of chronic obstructive pulmonary disorder using the principles of 'inhalation by design'. A key feature of this work is th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf2972c74e7582b1b629c2304ccadb40
https://pubmed.ncbi.nlm.nih.gov/21075627
https://pubmed.ncbi.nlm.nih.gov/21075627
Optimized glucuronidation of dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD
Autor:
Rachel Osborne, David A. Entwistle, Michael Yeadon, Graham Lunn, Karen N. Wright, Jane L. Burrows, Emilio F. Stuart, Lyn H. Jones, Sandra D. Newman, Kim James, Amy S. Kenyon, Fiona J. Spence, Susan Summerhill, Matthew D. Selby, Nick Clarke, David Price, Stuart Marshall, Laura Hilton, Helen Baldock, Rhys M. Jones, Neil Feeder, Michael A. Trevethick, Sheena Patel, Nadia Laouar, Michele Coghlan, Mark E. Bunnage, David Fairman
Publikováno v:
MedChemComm. 2:870
‘Inhalation by design’ concepts were developed to create novel dual pharmacology β-2 agonists-M3 antagonists, for the treatment of chronic obstructive pulmonary disorder. A key feature of this work is the combination of balanced potency and phar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8e88fd334de3783a85ab6566fddbc69
https://doi.org/10.1039/c1md00140j
https://doi.org/10.1039/c1md00140j